Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Annovis Bio Inc
(NY:
ANVS
)
5.350
-0.040 (-0.74%)
Official Closing Price
Updated: 4:10 PM EDT, May 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Annovis Bio Inc
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
September 09, 2022
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to...
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 24, 2022
Via
Benzinga
FDA Gives Green Signal To Annovis Bio's Parkinson's Trial With Buntanetap
July 07, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2022
September 08, 2022
Via
Benzinga
Annovis Shares Gain As Late-Stage Parkinson's Disease Study Takes-off
August 24, 2022
Annovis Bio, Inc. (NYSE: ANVS) has initiated patient dosing in the Phase 3 clinical trial evaluating buntanetap in early Parkinson's Disease (PD). The Phase 3 trial is designed to evaluate the...
Via
Benzinga
Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron
August 02, 2022
Recent publishing of Longeveron Inc.’s (NASDAQ: LGVN)
Via
Benzinga
Dear AMC Stock Fans, Mark Your Calendars for Aug. 4
July 07, 2022
AMC Entertainment (AMC) stock is in the news today as investors in the theater company prepare for a potential catalyst coming next month!
Via
InvestorPlace
Annovis Bio (ANVS) Stock Soars 6% on Positive FDA Update
July 07, 2022
Annovis Bio (ANVS) stock is soaring higher on Thursday following a positive update from the FDA for its buntanetap clinical trial.
Via
InvestorPlace
Annovis Bio Gets FDA Nod For Late-Stage Parkinson Disease Study Amendments
July 07, 2022
The United States Food and Drug Administration (FDA) announced clearance for amendments to Annovis Bio’s (NYSE: ANVS) Phase 3 clinical study of Buntanetap for the treatment of Parkinson's disease.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
July 07, 2022
Via
Benzinga
83 Biggest Movers From Yesterday
June 09, 2022
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly...
Via
Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
June 08, 2022
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback.
Via
Benzinga
Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
May 04, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
May 02, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
April 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
April 28, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - April 28, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
April 11, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
March 23, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)
March 18, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - March 18, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022
March 08, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - March 8, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference
March 03, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - March 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease
January 25, 2022
Annovis Bio Inc (NYSE: ANVS) has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's...
Via
Benzinga
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
January 25, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - January 25, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Exposures
Product Safety
Annovis Bio Enhances Leadership Team with Two Senior Appointments
January 10, 2022
Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory OperationsCompany Promotes Cheng Fang, Ph.D., to Senior Vice...
Via
Newsfile
Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401
January 05, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences
January 03, 2022
Berwyn, Pennsylvania--(Newsfile Corp. - January 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
12 Health Care Stocks Moving In Monday's After-Market Session
December 27, 2021
Gainers OptiNose (NASDAQ:OPTN) shares mov...
Via
Benzinga
Annovis Bio on Its Positive Results in Alzheimer's and Parkinson's Clinical Trials
December 27, 2021
Image provided by Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
December 20, 2021
Berwyn, Pennsylvania--(Newsfile Corp. - December 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage...
Via
Newsfile
Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
December 14, 2021
Berwyn, Pennsylvania--(Newsfile Corp. - December 14, 2021) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...
Via
Newsfile
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.